Vector Platform MVA-CR19 - Technology for Virals

MVA is safe and versatile, but commercial access to this viral vector is severely restricted. We have derived our own IP-protected MVA-CR19. Compared to the original, the CR19 strain, it produces higher titers and is less dependent on cell-to-cell contacts for replication. In principle, this feature enables continuous production and purification processes from the supernatant and without cell lysis. We have also equipped CR19 with a smart and rapid recombination technology that facilitates the generation of recombinant vectors and shortens development times from several weeks to days.

The screening of multiple candidate constructs and the supply with vectors for personalized medicine require a fast turnover with regard to the design and generation of appropriate recombinant viruses. We have developed a rapid recombination platform that makes it possible to obtain the desired recombinants free of contamination with parental virus within a single passage. Only the parental virus and a shuttle plasmid, including the gene of interest, are required. The system is suitable for the rescue of recombinant viruses, either in adherent cells or in suspension cells that proliferate in chemically-defined media. We use this technology based on MVA-CR19 as a service. However, it can also be licensed by customers for other poxviruses.